Therapeutics Agents for Neural Repair 2023
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 6683
Special Issue Editor
Interests: spinal cord injury; biomaterials; pharmacology; regeneration; immunomodulation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
An insult to the central nervous system (CNS) usually leads to permanent and irreversible pathological conditions. Events such as stroke, trauma, or neurodegenerative diseases have a strong impact on the physiological, psychological, and social behaviors of patients. For these reasons, it is urgent to develop therapeutic strategies that can specifically target these problems. Typically, the pathophysiology of these conditions entails several molecular as well as cellular events and, given its multifaceted nature, many conceptually different paths are under investigation to promote neural repair. This Special Issue is dedicated to “Therapeutic Agents for Neural Repair”, and it is mainly focused on the use of pharmaceutical agents administrated alone or in combination with other therapeutic approaches.
I sincerely hope that you will be able to contribute a research manuscript or review article dealing with your research in this area of investigation. The proposed topics include, but are not limited to, the following:
- Pathologies of the CNS (Parkinson's, Alzheimer’s, Huntington’s, multiple sclerosis, depression, autism, Machado–Joseph, amyotrophic lateral sclerosis, stroke, traumatic brain injury, and spinal cord injury).
- Therapeutic approaches (molecular therapy, cell therapy, gene therapy, deep brain/epidural stimulation, and tissue engineering).
- Personalized medicine.
- Biomarkers of disease.
- In vitro/ex vivo studies.
- In vivo preclinical studies.
- Clinical studies.
I look forward to your participation.
Dr. Nuno A. Silva
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Related Special Issues
- Therapeutics Agents for Neural Repair 2023 in Pharmaceuticals (4 articles)
- Therapeutics Agents for Neural Repair 2023 in Pharmaceuticals (4 articles)